Xiromed launches generic Adrucil
Adrucil and its generics had a market value of $22.2 million for the 12-month period ended June 2021, according to IQVIA.
Xiromed is introducing fluorouracil injection in a dosage strength of 50mg/mL.
The medication is the generic of Adrucil.
Adrucil and its generics have a market value of $22.2 million, for the 12-month period ended June 2021, according to IQVIA.
Xiromed CEO Narasimhan Mani said, “The launch of fluorouracil injection 50mg/mL is the latest offering in our institutional portfolio as we continue to invest in a growing injectable pipeline to provide generic products to the U.S. market.”